AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
Rhea-AI Summary
Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 9:20 a.m. ET. Peter Griffith, CFO, and Jasper van Grunsven, SVP of Rare Disease, will take part in a fireside chat. The event will be webcast live and archived for at least 90 days.
The webcast will be available to media, investors, and the public via Amgen's Investor Relations Events Calendar and archived on Amgen's website for replay.
Positive
- None.
Negative
- None.
News Market Reaction – AMGN
In the Mar 6 session, AMGN gained 0.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Investor conference | Neutral | +0.4% | TD Cowen health care conference webcast and management presentation details. |
| Feb 13 | Investor conference | Neutral | +1.1% | Citi virtual oncology leadership summit appearance and webcast access. |
| Feb 03 | Earnings results | Positive | +8.2% | Q4 and 2025 results with revenue, product sales and GAAP EPS growth. |
| Jan 28 | Earnings webcast | Neutral | +0.2% | Scheduling and webcast details for Q4 and full-year 2025 results call. |
| Jan 20 | Legal action | Negative | +0.2% | Lawsuit over prescription drug access involving a large pharmaceutical company. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent AMGN news, including conference appearances and earnings updates, often coincided with modestly positive price reactions, with only a lawsuit headline showing divergence.
This announcement continues a pattern of AMGN engaging regularly with investors through conferences and webcasts. In late February and mid-February, the company highlighted appearances at the TD Cowen and Citi oncology conferences, each followed by small positive moves. Earlier, Q4 and full-year 2025 earnings showed higher revenues and GAAP EPS, with a stronger price reaction. A prior webcast announcement and a lawsuit headline produced only mild moves. Today’s Leerink conference notice fits this cadence of ongoing investor communication atop recently reported financial strength.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its
Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference-302705704.html
SOURCE Amgen